Bordry N, Astaras C, Ongaro M, Goossens N, Frossard JL, Koessler T. Recent advances in gastrointestinal cancers. World J Gastroenterol 2021; 27(28): 4493-4503 [PMID: 34366620 DOI: 10.3748/wjg.v27.i28.4493]
Corresponding Author of This Article
Thibaud Koessler, MD PhD, Chief Doctor, Doctor, Department of Oncology, University Hospital of Geneva (HUG), rue Gabrielle Perret-Gentil 4, 1211, Genève 1205, Switzerland. thibaud.kossler@hcuge.ch
Research Domain of This Article
Oncology
Article-Type of This Article
Guideline Interpretation
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jul 28, 2021; 27(28): 4493-4503 Published online Jul 28, 2021. doi: 10.3748/wjg.v27.i28.4493
Recent advances in gastrointestinal cancers
Natacha Bordry, Christoforos Astaras, Marie Ongaro, Nicolas Goossens, Jean Louis Frossard, Thibaud Koessler
Natacha Bordry, Christoforos Astaras, Thibaud Koessler, Department of Oncology, University Hospital of Geneva (HUG), Genève 1205, Switzerland
Marie Ongaro, Nicolas Goossens, Jean Louis Frossard, Divison of Gastroenterology and Hepatology, University Hospital of Geneva (HUG), Genève 1205, Switzerland
Author contributions: Bordry N, Astaras C and Koessler T designed the study and wrote the manuscript; Ongaro M, Goossens N and Frossard JL reviewed and corrected the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Thibaud Koessler, MD PhD, Chief Doctor, Doctor, Department of Oncology, University Hospital of Geneva (HUG), rue Gabrielle Perret-Gentil 4, 1211, Genève 1205, Switzerland. thibaud.kossler@hcuge.ch
Received: January 28, 2021 Peer-review started: January 28, 2021 First decision: March 29, 2021 Revised: April 11, 2021 Accepted: July 5, 2021 Article in press: July 5, 2021 Published online: July 28, 2021 Processing time: 178 Days and 12.6 Hours
Abstract
Gastrointestinal cancers occur in a total of eight different locations, each of them with a different standard of care. This article is not an exhaustive review of what has been published in 2020. We have concentrated on the thirteen phase III randomized studies that are practice-changing. All these studies are oral presentations which have been given in one of the four major oncology congresses, namely American Society of Clinical Oncology (ASCO), ASCO gastrointestinal (GI), European Society of Medical Oncology (ESMO) and ESMO-GI. We provide a concise view of these major trials and their main outcomes, and put these results into context.
Core Tip: Gastrointestinal cancers are one of the most frequent cancers and a leading cause of cancer deaths worldwide. Gastroenterologists, hepatologists and visceral surgeons interact daily with these patients. Bringing the community up to speed with new treatment paradigms in gastrointestinal oncology could improve patient care. Here we provide a clear, comprehensive and short overview of the most important practice changing trials from 2020.
